Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2019

MSD signs pain medications deal with King’s College and Wellcome

Pharmaceutical company MSD has signed an agreement with King’s College London and non-profit Wellcome Trust in the UK for the development of a new generation of pain medications.

Pharmaceutical company MSD has signed an agreement with King’s College London (KCL) and the non-profit Wellcome Trust in the UK for the development of a new generation of pain medications.

Existing painkillers are designed to relieve short-term pain. However, these pills are much less effective for chronic pain and associated with a risk of averse side-effects when high doses are taken over time.

Under the collaboration and licence deal, MSD will pay up to $340m in development and sales milestones, and royalties to King’s and Wellcome, if a drug comes to market.

“Chronic pain has a devastating effect on people’s lives. By targeting the molecular causes of pain we have developed new molecules that we believe can avoid the major side-effects that come with current painkillers.”

The latest alliance is based on research by professor Peter McNaughton at King’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN), who in 2011 discovered a biological mechanism responsible for chronic neuropathic pain.

While working at the University of Cambridge, McNaughton found that a protein called HCN2 plays a key role in chronic pain and can cause a continuous pain sensation by triggering electrical signals in nerve fibres.

After moving to KCL’d Wolfson Centre for Age-Related Diseases, the professor and his team identified that blocking HCN2 activity in animal models can provide effective pain relief without side effects which patients find unpleasant.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Since 2012, Wellcome granted £4.5m to support McNaughton’s work on developing drug candidates to block the HCN2 protein.

As part of the collaboration, MSD will carry out lead optimisation, preclinical development and clinical trials. The company will also fund further research on biological mechanisms of pain at the McNaughton lab.

McNaughton said: “Chronic pain has a devastating effect on people’s lives. Most pain drugs have been developed from traditional remedies or by repurposing existing medications and in general are not very effective at controlling chronic pain.

“By targeting the molecular causes of pain we have developed new molecules that we believe can avoid the major side-effects that come with current painkillers.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU